Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Changes in Beneficial Ownership · 4

Scribe Therapeutics Inc.

SCTXNASDAQEQUITYCurrent

Changes in Beneficial Ownership

Filed Jul 29, 2026Accepted Jul 29, 2026, 7:09 PM EDTFiling CIK 1853921Accession 0001231919-26-000813
Share

Structured filing — 4

form4-07292026_110744.xml

Open full document ↗

Filing details

Report period
2026-07-27
Issuer
Scribe Therapeutics, Inc.
Issuer CIK
0001853921
Trading symbol
SCTX

Reporting owner 1

Name
AH Bio Fund II, L.P.
Reporting owner CIK
0001725721
Relationship
10% owner
Address
C/O ANDREESSEN HOROWITZ, 2865 SAND HILL ROAD, SUITE 101, MENLO PARK, CA, 94025

Reporting owner 2

Name
AH Equity Partners Bio II, L.L.C.
Reporting owner CIK
0001725722
Relationship
10% owner
Address
C/O ANDREESSEN HOROWITZ, 2865 SAND HILL ROAD, SUITE 101, MENLO PARK, CA, 94025

Reporting owner 3

Name
AH Bio Fund III, L.P.
Reporting owner CIK
0001799477
Relationship
10% owner
Address
C/O ANDREESSEN HOROWITZ, 2865 SAND HILL ROAD, SUITE 101, MENLO PARK, CA, 94025

Reporting owner 4

Name
AH Equity Partners Bio III, L.L.C.
Reporting owner CIK
0001799478
Relationship
10% owner
Address
C/O ANDREESSEN HOROWITZ, 2865 SAND HILL ROAD, SUITE 101, MENLO PARK, CA, 94025

Reporting owner 5

Name
Andreessen Marc L
Reporting owner CIK
0001160077
Relationship
10% owner
Address
C/O ANDREESSEN HOROWITZ, 2865 SAND HILL ROAD, SUITE 101, MENLO PARK, CA, 94025

Reporting owner 6

Name
HOROWITZ BENJAMIN A
Reporting owner CIK
0001166586
Relationship
10% owner
Address
C/O ANDREESSEN HOROWITZ, 2865 SAND HILL ROAD, SUITE 101, MENLO PARK, CA, 94025

Non-derivative transactions

Non-derivative transactions · 3 reported rows
SecurityTransaction dateCodeAmountA / DPrice (USD)Owned afterOwnershipNature of ownership
Common Stock2026-07-27C · Form 42,051,742A[F1]2,051,742IBy AH Bio Fund II, L.P.[F2]
Common Stock2026-07-27C · Form 4697,650A[F1]697,650IBy AH Bio Fund III, L.P.[F3][F4]
Common Stock2026-07-27P · Form 4333,333A152,385,075IBy AH Bio Fund II, L.P.[F2]
Table key
C · Form 4
Derivative conversion
A
Acquired
I
Indirect
P · Form 4
Purchase on the market or privately

Derivative transactions

Derivative transactions · 2 reported rows
SecurityConversion / exercise price (USD)Transaction dateCodeAmountA / DPrice (USD)ExercisableExpiresUnderlying securityUnderlying sharesOwned afterOwnershipNature of ownership
Series A Preferred Stock[F1]2026-07-27C · Form 412,150,003D0[F1][F1]Common Stock2,051,7420IBy AH Bio Fund II, L.P.[F2]
Series B Preferred Stock[F1]2026-07-27C · Form 44,131,344D0[F1][F1]Common Stock697,6500IBy AH Bio Fund III, L.P.[F3][F4]
Table key
C · Form 4
Derivative conversion
D
Disposed
I
Indirect

Footnotes

F1
Series A Preferred Stock and Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 5.9218-for-one basis, and had no expiration date.↩ 1↩ 2↩ 3↩ 4↩ 5↩ 6↩ 7↩ 8
F2
The reported securities are held by AH Bio Fund II, L.P. ("AH Bio Fund II"), for itself and as nominee for AH Bio Fund II-B, L.P. AH Equity Partners Bio II, L.L.C. ("AH EP Bio II") is the general partner of AH Bio Fund II and has sole voting and dispositive power with regard to the securities held by AH Bio Fund II for itself and as nominee. The managing members of AH EP Bio II are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund II for itself and as nominee. Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of the securities held by AH Bio Fund II for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any.↩ 1↩ 2↩ 3
F3
The reported securities are held by AH Bio Fund III, L.P. ("AH Bio Fund III"), for itself and as nominee for AH Bio Fund III-B, L.P., AH Bio Fund III-Q, L.P. and CLF Partners II, LP. AH Equity Partners Bio III, L.L.C. ("AH EP Bio III") is the general partner of AH Bio Fund III and has sole voting and dispositive power with regard to the securities held by AH Bio Fund III for itself and as nominee. The managing members of AH EP Bio III are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund III for itself and as nominee.↩ 1↩ 2
F4
(Continued from Footnote 3) Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of the securities held by AH Bio Fund III for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any.↩ 1↩ 2

Signature 1

Signed
AH Bio Fund II, L.P., By AH Equity Partners Bio II, L.L.C., Its General Partner, By /s/ Phil Hathaway, Chief Operating Officer
Date
2026-07-29

Signature 2

Signed
AH Equity Partners Bio II, L.L.C., By /s/ Phil Hathaway, Chief Operating Officer
Date
2026-07-29

Signature 3

Signed
AH Bio Fund III, L.P., By AH Equity Partners Bio III, L.L.C., Its General Partner, By /s/ Phil Hathaway, Chief Operating Officer
Date
2026-07-29

Signature 4

Signed
AH Equity Partners Bio III, L.L.C., By /s/ Phil Hathaway, Chief Operating Officer
Date
2026-07-29

Signature 5

Signed
/s/ Phil Hathaway, Attorney-in-Fact for Marc L. Andreessen
Date
2026-07-29

Signature 6

Signed
/s/ Phil Hathaway, Attorney-in-Fact for Benjamin Horowitz
Date
2026-07-29

Company context

We are a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention. While current genetic medicines are largely limited to rare disorders, we are engineering our technologies for use in common diseases affecting millions. By targeting prevalent diseases with significant unmet need and high clinical burden, we aim to usher in a new era of broadly scalable, transformative, and preventative genetic medicines. Our focus is on cardiovascular and metabolic diseases with initial programs to address the key drivers of atherosclerotic cardiovascular disease, or ASCVD. We are designing CRISPR-based genetic medicines to be well-tolerated, effective, durable, and scalable enough to shift the treatment paradigm from symptom-driven intervention and chronic care to population-level prevention, with the goal of broadly democratizing access to the cardioprotective effects of known genetic variants. Our lead product candidate, STX-1150, utilizes ELXR, our highly engineered epigenetic silencing technology, and is designed to deliver persistent and potent LDL-C reductions without permanent genetic changes. STX-1150 is a demonstration of moving towards our goal to transform practical therapeutic adherence and real-world medical outcomes for patients in the multibillion-dollar LDL-C lowering landscape. We have secured regulatory clearance from the Australian Therapeu

Current securities

Recent company filings

  1. SCHEDULE 13G - filed by AH Bio Fund II, L.P. regarding Scribe Therapeutics, Inc.Nov 16, 2026
  2. 10-Q filingNov 12, 2026
  3. Results of Operations and Financial ConditionNov 12, 2026
  4. 10-Q filingSep 2, 2026
  5. Results of Operations and Financial ConditionSep 2, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.